Full Press Release Details
• CHF137 million ($111 million / €83 million) raised in Swiss IPO in MayCHF159 million ($129 million / €96 million) in cash as of 30 June 2007ADX10059 met the primary efficacy endpoint in a Phase IIa GERD trialADX10059 met the primary efficacy endpoint in a Phase IIa migraine trialADX10059 Phase IIa anxiety data due around the end of the yearADX10061 Phase IIa smoking cessation data due around the end of 3Q07
| Date:Time: | 25 July 200715.30 ~ 16.30 CEST (9:30 ~ 10:30am EDT) | |
| Dial-in numbers: | +41 91 610 56 00+44 207 107 0611+1 866 291 4166 | (Europe)(UK)(USA) |
| Chris Maggos | Katia Spartalli |
| Head of Investor Relations & Communications | Executive Secretary |
| Addex Pharmaceuticals | Addex Pharmaceuticals |
| Tel: +41 22 884 15 11 | Tel. + 41 22 884 15 99 |
| chris.maggos@addexpharma.com | katia.spartalli@addexpharma.com |